Company
Headquarters: Heze, China
Employees: 1,110
CN¥2.30 Billion
CNY as of July 1, 2024
US$316.3 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $121.36 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Shandong Sito Bio-technology Co., Ltd. researches and develops new steroid hormones, intermediates, and derivatives. Its products include 9a-hydroxyandrostenedione, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, dexamethasone epoxy hydrolysate, progesterone intermediate, opener, tetraene, androstenedione, ketal, acid removal, 3-ketal, and betamethasone epoxy hydrolyzate, as well as 1,4-androstenedione. The company was founded in 2002 and is based in Heze, China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Shandong Sito Bio-technology Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300583 wb_incandescent